Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 …

Research highlights include data from Addex` programs in Alzheimer`s, Parkinson`s, psychiatry indications and post-traumatic stress disorder

Geneva, Switzerland, 11 October 2012 - Addex Therapeutics (ADXN.SW), a leading company pioneering allosteric modulation-based drug discovery and development, announced today the company will present data from three of its innovative allosteric modulation programs targeting G-protein coupled receptors (GPCRs) at the Society for Neuroscience 2012 meeting next week (October 13-17). The programs that will be showcased at the meeting include:

ADX92639: a potent and selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 2 (mGluR2) that has the potential to treat a number of diseases, including improving cognition and Alzheimer`s disease. In an oral presentation at the conference, data demonstrating ADX92639-mediated improvement in recognition memory in validated rodent models of Alzheimer`s disease will be discussed. The selectivity of ADX92639 for mGluR2 differentiates the compound from other approaches targeting this important receptor.

Dipraglurant: a clinical stage potent oral small molecule NAM targeting mGluR5 that has the potential to treat a variety of indications, including Parkinson`s disease levodopa-induced dyskinesia (PD-LID), dystonia, anxiety, and depression. Data will be presented in two poster sessions, one on the translational value of the MPTP non-human primate model of PD-LID to the clinical utility of dipraglurant; and a second about the treatment of non dyskinetic complications with dipraglurant, i.e., affective disorders and compulsive behaviors.

ADX71743: a potent and selective NAM of mGluR7. Data generated with this unique molecule will be presented in a poster at the conference, unraveling some key physiological roles of mGluR7, and suggesting that its pharmacological blockade may represent a new avenue for the treatment of anxiety, drug abuse and cognitive function disorders, such as depression and post-traumatic stress disorder (PTSD).

"Each of these exciting programs originates from our proprietary allosteric modulation technology platform. Our research and the data presented at the Conference demonstrate the significant progress we are making in translating the promise of allosteric modulation towards a new class of oral small molecule therapeutics. These innovative, potent and highly selective allosteric modulators are being developed to address important GPCR targets that have previously been deemed "undruggable" using conventional approaches." explained Dr Graham Dixon, CSO of Addex Therapeutics. "We believe that these allosteric modulators have the potential to transform the treatment of several important neurological diseases that are not adequately being treated with the current standards of care."

Society for Neuroscience 2012 presentations include:

Monday, Oct 15, 20129:00 - 10:00 AMADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGluR7), Hall F-J Program/Poster #359.06/Y12

Tuesday, Oct 16, 20128:00 - 9:00 AMEffect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on non-motor symptoms of Parkinson`s disease, Hall F-J Program/Poster #546.09/F41

Link:
Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 ...